Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
Tolcher, Anthony W., Kurzrock, Razelle, Valero, Vincente, Gonzalez, Rene, Heist, Rebecca S., Tan, Antoinette R., Means-Powell, Julie, Werner, Theresa L., Becerra, Carlos, Wang, Chenxi, Leonowens, CathJournal:
Cancer Chemotherapy and Pharmacology
DOI:
10.1007/s00280-020-04038-8
Date:
February, 2020
File:
PDF, 679 KB
2020
File converter
More search results
More benefits 
